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Abstract
Rationale Synthesis of ligands inactive or with low activity
at α1 GABAA receptors has become the key concept for
development of novel, more tolerable benzodiazepine (BZ)-
like drugs. WYS8, a remarkably (105 times) α1-subtype
selective partial positive modulator, may serve as a pharma-
cological tool for refining the role of α1 GABAA receptors
in mediation of BZs’ effects.
Objectives Here, the effects of WYS8 on GABA-induced
currents and on diazepam-induced potentiation of recombi-
nant BZ-sensitive GABAA receptors were studied in more
detail. In addition, the behavioral profile ofWYS8 (0.2, 1, and
10 mg/kg i.p.), on its own and in combination with diazepam,
was tested in the spontaneous locomotor activity, elevated
plus maze, grip strength, rotarod, and pentylenetetrazole tests.
Results WYS8, applied at an in vivo attainable concentration
of 100 nM, reduced the stimulation of GABA currents by
1 μM diazepam by 57 % at α1β3γ2, but not at α2β3γ2,
α3β3γ2, or α5β3γ2 GABAA receptors. The administration
of WYS8 alone induced negligible behavioral consequences.
When combined with diazepam, WYS8 caused a reduction in
sedation, muscle relaxation, and anticonvulsant activity, as
compared with this BZ alone, whereas ataxia was preserved,
and the anxiolytic effect of 2 mg/kg diazepam was unmasked.
Conclusions Hence, a partial instead of full activation at α1
GABAA receptors did not necessarily result in the attenua-
tion of the effects assumed to be mediated by activation of
these receptors, or in the full preservation of the effects
mediated by activation of other GABAA receptors. Thus,
the role of α1 GABAA receptors appears more complex than
that proposed by genetic studies.
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Introduction
The last two decades have witnessed numerous break-
throughs in understanding the mechanisms of action of
psychopharmacologic drugs, which were originally intro-
duced into clinical practice mainly without clear-cut knowl-
edge of the intricate receptor substrates underlying their
pharmacological actions (Fibiger 2012). From the applica-
tive point of view, the final goal of these efforts would be to
introduce novel, receptor-selective ligands which clinically
separate wanted from unwanted effects. The research field
of the benzodiazepines (BZs), positive allosteric modulators
of the BZ binding site at GABAA receptors in the central
nervous system, has been thought of as especially promising
in this regard. Namely, these widely used drugs clinically act
through no more than four major GABAA receptor
populations, which contain the α1, α2, α3, or α5 subunit in
addition to a β and the γ2 subunit (Chang et al. 1996) and
have distinct patterns of anatomical distribution in the brain
(Sieghart and Ernst 2005). Thus, it was logical to hypothe-
size that each of the receptor subtypes may mediate a
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distinct set of BZ effects, allowing synthesis of ligands
which modulate only receptor(s) involved in clinically
wanted actions (Dawson et al. 2005).
The studies with point-mutated mice, made insensitive to
diazepam at only one of four populations of BZ-sensitive
GABAA receptors, have attributed the sedative and ataxic
properties of this standard BZ to the α1 subunit-containing
GABAA receptor, the anxiolytic and muscle relaxant actions
to the α2/α3 subtype-containing receptors, and anticonvul-
sant activity, in part, to all the α1/α2/α3 GABAA receptors
(reviewed in Rudolph and Möhler 2004). Based on these
results, inactivity/low-activity at α1 GABAA receptors has
evolved as the key concept for development of new BZ-like
drugs, purportedly devoid of many adverse effects of stan-
dard BZs, such as sedation or abuse liability (Dawson et al.
2005; Rudolph and Knoflach 2011). However, generaliza-
tion of this concept in the quest for anxioselective anxio-
lytics has been questioned by the findings in humans that
several ligands, reportedly possessing properties of either
null or low efficacy at α1 GABAA receptors, still exerted the
effects reflective of sedation (reviewed in Skolnick 2012).
These failures in clinical development have tempered orig-
inal enthusiasm, clearly demanding refinement in the con-
cept of preclinical research.
While it is perceivable that inactivation of a whole re-
ceptor population by a point mutation is suitable for the
identification of main effects of one receptor subtype, such
an approach cannot be expected to allow the identification
of a possible subtle modulation of behavioral effects primar-
ily mediated by other receptors (cf. Morris et al. 2006).
However, it could be possible to observe such subtle mod-
ulation when the effects of diazepam mediated by certain
receptor subtypes are not nullified by point mutations but
only inhibited by selective antagonists. The effects of BZs
mediated by α1 GABAA receptors have been studied using
pharmacological manipulation with the approximately 20
times α1-subunit selective neutral modulator (antagonist)
β-CCt (t-butyl-β-carboline-3-carboxylate) (Rowlett et al.
2005). In addition, recently we have demonstrated that
WYS8 (8-ethynyl-β-carboline-3-carboxylate-t-butyl ester),
a close congener of β-CCt with even higher selectivity in
affinity for α1 GABAA receptors (Yin et al. 2010), behaves
as a weak partial positive modulator (Joksimović et al.
2013). When combined with diazepam, the in vivo actions
of these two close congeners were clearly differentiable: β-
CCt proved to be an antagonist of diazepam’s effects (Savić
et al. 2009), while WYS8 not only did not antagonize but
even potentiated some of diazepam’s effects in the water
maze (Joksimović et al. 2013).
Here, we present a wider set of electrophysiological data on
WYS8 and also report on the in vitro selectivity in its antag-
onism of diazepam’s effects exerted through α1-containing
but not other BZ-sensitive GABAA receptors. Furthermore,
the present study investigated WYS8 on its own and in
combination with diazepam in behavioral procedures
designed to assess the sedative, anxiolytic, muscle relaxant,
ataxic, and anticonvulsant effects of positive modulators at the
BZ binding site with the aid of the spontaneous locomotor




The novel compound WYS8 (8-ethynyl-ß-carboline-3-car-
boxylate-t-butyl ester; 8-ethynyl-ß-CCt) was synthesized at
the Department of Chemistry and Biochemistry, University
of Wisconsin-Milwaukee. For electrophysiological study,
diazepam was purchased from Sigma-Aldrich, St. Louis,
MO, USA while, for behavioral experiments, diazepam
was obtained from Galenika (Belgrade, Serbia).
Two electrode voltage clamp
cDNAs of rat GABAA receptor subunits were used for
generating the respective mRNA's that were then injected
into Xenopus laevis oocytes (Nasco, WI) as described pre-
viously (Ramerstorfer et al. 2010). For electrophysiological
recordings, oocytes were placed on a nylon-grid in a bath of
Xenopus Ringer solution (XR, containing 90 mM NaCl,
5 mM HEPES–NaOH (pH 7.4), 1 mM MgCl2, 1 mM KCl,
and 1 mM CaCl2). The oocytes were constantly washed by a
flow of 6 ml/min XR which could be switched to XR
containing GABA and/or drugs. Drugs were diluted into
XR from dimethyl sulfoxide (DMSO)-solutions resulting
in a final concentration of 0.1 % DMSO perfusing the
oocytes. Drugs were preapplied for 30 s before the addition
of GABA, which was coapplied with the drugs until a peak
response was observed. Between two applications, oocytes
were washed in XR for up to 15 min to ensure full recovery
from desensitization. To test for modulation of GABA-
induced currents by drugs, a concentration of GABA was
used that was titrated to trigger 3 % of the respective
maximum GABA-elicited current of the individual oocyte
(EC3). At this low GABA concentration, within- and
between-day currents are reproducible and effects of drugs
(percent of modulation) are much higher than that at higher
GABA concentrations, contributing to the accuracy of the
results. In addition, such low GABA concentrations corre-
spond to those acting at extrasynaptic receptors that repre-
sent the majority of GABAA receptors in the brain (Kasugai
et al., 2010). In contrast, GABA concentrations acting at
synaptic GABAA receptors in many cases fully activate
these receptors. At such GABA concentrations, benzodiaz-
epines cannot enhance GABA currents anymore, but they
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prolong current decay. This effect, however, is antagonized
by a simultaneously occurring rapid receptor desensitization
making measurements unreliable. The GABA EC3 concen-
tration was applied to the cell together with various concen-
trations of drugs. For current measurements, the oocytes
were impaled with two microelectrodes (2–3 mΩ) which
were filled with 2 mM KCl. All recordings were performed
at room temperature at a holding potential of −60 mV using
a Warner OC-725C two-electrode voltage clamp (Warner
Instruments, Hamden, CT). Data were digitized, recorded,
and measured using a Digidata 1322A data acquisition
system (Axon Instruments, Union City, CA). Results of
concentration response experiments were graphed using
GraphPad Prism 4.00 (GraphPad Software, San Diego,
CA). Data were graphed as mean±SEM of at least four
oocytes from at least two batches.
In addition to experiments performed previously
(Joksimović et al. 2013), the presently performed experi-
ments aimed to obtain: (1) concentration effect curves for
WYS8 at recombinant α4β3γ2 and α6β3γ2, as well as at
α1β1γ2, α1β2γ2 and α1β3γ2 GABAA receptors; (2) elec-
trophysiological recordings for 1 μM diazepam and 10 nM,
100 nM, and 1 μM WYS8, on their own and in respective
combinations at α1β3γ2GABAA receptors, and for 1 μM
diazepam and 100 nM WYS8, on their own and in combi-
nation at α2β3γ2, α3β3γ2, and α5β3γ2GABAA receptors.
Behavioral experiments
Experiments were carried out on male Wistar rats (Military
Farm, Belgrade, Serbia), weighing 220–250 g. All proce-
dures in the study conformed to EEC Directive 86/609 and
were approved by the Ethical Committee on Animal
Experimentation of the Faculty of Pharmacy in Belgrade.
The rats were housed in transparent plastic cages, six animals
per cage, and had free access to food pellets and tap water. The
temperature of the animal room was 22±1 °C, the relative
humidity 40–70 %, the illumination 120 lux, and the 12/12 h
light/dark period (light on at 6:00 h). All handling and testing
took place during the light phase of the diurnal cycle (testing
started at 9:00 h). Separate groups of animals were used for all
behavioral paradigms, with the exception of the grip strength
and pentylenetetrazole test, which were consecutively
performed in the same animals. The rats’ behavior in the
spontaneous locomotor activity and the elevated plus maze
was recorded by a ceiling-mounted camera and analyzed by
the ANY-maze Video Tracking System software (Stoelting Co.,
Wood Dale, IL, USA). In the spontaneous locomotor activity
test, grip strength, and pentylenetetrazole test, we used eight
treatment groups altogether: solvent, diazepam (2 mg/kg),
WYS8 (0.2, 1, and 10 mg/kg), diazepam (2 mg/kg)+WYS8
(0.2, 1, and 10 mg/kg). In the elevated plus maze and rotarod,
we added four more groups: diazepam (1 mg/kg) and diazepam
(1 mg/kg)+WYS8 (0.2, 1, and 10 mg/kg) or diazepam
(0.5 mg/kg) and diazepam (0.5 mg/kg)+WYS8 (0.2, 1, and
10 mg/kg), respectively. The ligands were dissolved/suspended
with the aid of sonication in a solvent containing 85 % distilled
water, 14 % propylene glycol, and 1 % Tween 80 and were
administered intraperitoneally in an overall volume of 2 ml/kg,
20 min before behavioral testing.
Measurement of locomotor activity
Twenty minutes after receiving the appropriate treatment,
single rats were placed in a clear Plexiglas chamber (40×
25×35 cm). Activity under dim red light (20 lux) was
recorded for a total of 30 min, without any habituation
period. Besides the total distance traveled, behavior was
analyzed by dividing the locomotor activity data into 5-
min bins.
Behavior in the elevated plus maze
The apparatus was constructed of sheet metal, with a black
rubber floor. It consisted of a maze elevated to a height of
50 cm with two open (50×10 cm) and two enclosed arms
(50×10×40 cm), connected by a junction area (central
platform) measured 10×10 cm. A ledge of sheet metal
(0.3 cm high) surrounding the open arms was added. The
illumination in the experimental room consisted of one red
neon tube fixed on the ceiling, giving light intensity of
10 lux on the surface of the closed arms. At the beginning
of the experiment, single rats were placed in the center of the
maze, facing one of the enclosed arms, and their behavior
was recorded for 5 min. An entry into an open or closed arm
was scored when 90 % of the animal crossed the virtual line
separating the central square of the maze from the arm,
whereas an exit occurred when more than 90 % of the
animal left the respective arm. After each trial, the maze
was cleaned with dry and wet towels.
Grip strength test
Muscle strength was assessed by the grip strength meter
(Ugo Basile, Milan, Italy, model 47105). When pulled by
the tail, the rat grasps the trapeze connected to a force
transducer, and the apparatus measures the peak force of
experimenter’s pull (in grams) necessary to overcome the
strength of the animal’s forelimbs grip. Each animal was
given three consecutive trials, and the median value of three
readings was used for further statistics.
Rotarod performance
Rotarod test (Ugo Basile, Comerio, Italy) measured the capac-
ity of the animal to maintain itself on the revolving rod. The
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rats were trained for 4 days, with three 2-min trials each day.
On the first training day, speed of revolutions was fixed at
15 rpm while, afterwards, an acceleration 15–25 rpm was
imparted. In the morning of the fifth day, the final selection
was made. Only animals capable of remaining 120 s on the
rod, without any fall, were chosen for further testing. The
rotarod performance was tested 20 min after treatment.
Pentylenetetrazole test
Pentylenetetrazole (70 mg/kg) was used as a standard chem-
ical convulsant eliciting, according to our preliminary ex-
periments, a characteristic epileptic-like syndrome in at least
80 % of rats. It was injected subcutaneously 20 min after the
pretreatment with WYS8 and/or diazepam. The protection
against clonic or tonic seizures during the 30-min observa-
tion period was considered as an index of anticonvulsant
activity.
Statistical analysis
For electrophysiological data, the paired Student’s t test was
used, comparing the means of the percent of GABA EC3
stimulation with a hypothetical value of 100 (100 % of
GABA EC3−control current). Data sets from behavioral
studies were checked for homogeneity of variance and nor-
mality prior to analysis by a two-way ANOVA (four levels
of factor WYS8 and two or three levels of factor diazepam).
Where applicable, Student–Newman–Keuls’s (SNK) test for
post hoc comparisons was also used. In the case of
significant interaction, separate one-way ANOVAs and
Student’s t tests were conducted to assess the influence
of one factor within individual levels of other factor. In
the pentylenetetrazole test, a chi-square test was
performed to determine if there was overall difference in
the frequency of incidence of clonic or tonic convulsions
due to pretreatment with different doses of WYS8 and/or
diazepam. Afterward, the two respective incidences were
compared by Fisher’s exact test. Statistical analyses were
performed with ANY-maze Video Tracking System soft-
ware (Stoelting Co., Wood Dale, IL, USA) and Sigma
Plot 11 (Systat Software Inc., Richmond, CA, USA).
Differences were considered to be statistically significant
when p was less than 0.05, while 0.1>p>0.05 was con-
sidered as a trend toward significance.
Results
Two-electrode voltage clamp
The in vitro concentration–effect curves presenting percent
potentiation of a within- and between-day stable GABA
EC3 response for WYS8 at recombinant α1–6β3γ2
GABAA receptors, together with the comparison of its ef-
fects at α1β1–3γ2 receptors, are given in Fig. 1. Besides
modulatory influences on α1-, α2-, α3-, and α5β3γ2
GABAA receptors, which have been published previously
(Joksimović et al. 2013), here, we additionally report on the
effects of WYS8 at BZ-insensitive α4- and α6-containing
GABAA receptor subtypes. In a manner analogous to the
actions of WYS8 at other non-α1 GABAA receptors, no
considerable modulation was reached at concentrations low-
er than 100 nM (α4 GABAA receptors) or 10 μM (α6
GABAA receptors) (Fig. 1). Potentiating actions at β1-,
β2-, and β3-containing α1 GABAA receptors were similar
to each other in a wide range of WYS8 concentrations
(1 nM–1 μM) (inset of Fig. 1).
Electrophysiological behavior of diazepam (at 1 μM),
WYS8 (at 100 nM), and their combinations is presented in
Fig. 2, together with explicit data on percent potentiation of
EC3 GABA response at rat recombinant α1-,α2-, α3-, and
α5β3γ2 GABAA receptors. In addition, Fig. 2 shows in vitro
activity at α1β3γ2 GABAA receptors of 10 nM and 1 μM
WYS8, on their own and in combination with 1 μM
Fig. 1 Main figure: Concentration–effect curves for WYS8 on α1β3γ2
(closed square), α2β3γ2 (triangle), α3β3γ2 (inverted triangle), α4β3γ2
(closed circle), α5β3γ2 (closed diamond), and α6β3γ2 (asterisk)
GABAA receptors, using an EC3 GABA concentration. Data points
in main figure and inset represent means±SEM from three to six
oocytes from ≥2 batches. The percentages of stimulation for BZ-
sensitive GABAA receptor subtypes have already been given in
Joksimović et al. (2013). A significant potentiation of α4β3γ2 recep-
tors was detected at 100 nM (114±3%), 1 μM (128±4%), and 10 μM
(203±10%) of WYS8. At α6β3γ2 receptors, only the highest concen-
tration of WYS8 resulted in a significant change relative to control
current (145±5%). Inset: In separate experiments performed in paral-
lel, a concentration of 10 nM of WYS8 resulted in 124±4%, 125±3%,
and 120±2% of control current in α1β1γ2, α1β2γ2, and α1β3γ2
GABAA receptors, respectively. The tenfold higher concentration of
WYS8 resulted in 126±5%, 131±4%, and 126±3% of control current
in α1β1γ2, α1β2γ2, and α1β3γ2 GABAA receptors, respectively. All
values given were significantly different from the respective control
currents (p<0.05, one sample Student’s t test)
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diazepam. While diazepam exerted significant potentiation
of GABA EC3 at all GABAA receptor subtypes, WYS8
behaved as a weak partially effective positive modulator at
α1β3γ2 and produced a borderline significant effect at
α3β3γ2 GABAA receptors; this pattern of activity was es-
sentially similar to that already reported (Joksimović et al.
2013). The addition of WYS8 at concentration of 100 nM
resulted in a significant reduction of diazepam’s potentiation
of only α1-containing GABAA receptors. At these receptors,
WYS8 also exerted a comparable attenuating effect at 1 μM
but not 10 nM.
Motor activity assay
A two-way ANOVA applied on the analysis of the in-
fluence on total distance traveled in the activity chamber
(Fig. 3) indicated a significant effect of the factor diazepam (F
(1,48)=11.02, p=0.002), whereas the dose of the WYS8 as a
factor was of borderline significance (F(3,48)=2.81,
p=0.050). The diazepam×WYS8 interaction was not signifi-
cant (F(3,55)=0.14, p=0.937). Post hoc SNK’s method
showed that there were no significant differences among
single levels of the factor WYS8; the greatest difference of
means (3.462 m) existed between doses of 0.2 and 10 mg/kg
(p=0.054). On the other hand, the existing significant differ-
ence of means (3.087 m) between the two levels of diazepam
(2 versus 0 mg/kg, p=0.002) was based on difference within
WYS8 0 (4.109 m, p=0.032) and disappeared when multiple
comparisons were made within the 0.2, 1, and 10 mg/kg
WYS8 doses (respective p values 0.148, 0.128, and 0.166),
showing that the sedative action of diazepam was attenuated
by addition of WYS8.
When the two-way ANOVA for traveled distance was
developed into 5-min intervals (Fig. 4), it turned out that the
influence of diazepam as a factor was significant in the
periods 0–5 min (F(1,48)=8.31, p=0.006) and 5–10 min
(F(1,48)=22.99, p<0.001). While the sedative effect of
diazepam in the first interval was based solely on the dif-
ference within the WYS8 0 level (difference of means
1.90 m, p=0.025), significant differences in the next interval
(5–10 min) were present within the 0, 0.2, and 1 mg/kg
WYS8 doses (respective differences of means 1.39
(p=0.036), 1.86 (p=0.06), and 1.67 m (p=0.013)); the
difference within the 10 mg/kg dose of WYS8 was
nearly significant (1.27 m, p=0.055). This analysis has shown
that there existed a short period when the sedative action of
Fig. 2 Bar graphs indicating the effects of diazepam (DZP; 1 μM),
WYS8 (10 nM, 100 nM, 1 μM) and their combination at αxβ3γ2
GABAA receptors, using an EC3 GABA concentration. Data points
represent means+SEM from at least three (n=3–8) oocytes from ≥2
batches. The concentration of 1 μM of diazepam resulted in 193±8%,
329±7%, 263±19%, and 318±12% of control current at α1-, α2-, α3-,
and α5β3γ2 GABAA receptors, respectively. The tested concentration
of WYS8 (100 nM) reached significance only at α1- and α3β3γ2
GABAA receptors (118±3% and 110±5%, respectively). The addition
of WYS8 (100 nM) to diazepam (1 μM) resulted in 140±5%, 297±
18%, 250± 17%, and 322±14% of control current at α1-, α2-, α3-, and
α5β3γ2 GABAA receptors, respectively. The WYS8 (10 nM)+diaze-
pam (1 μM) combination resulted in 182±7% of control current at
α1β3γ2 GABAA receptors. At the same receptor population, the addi-
tion of WYS8 (1 μM) to diazepam (1 μM) resulted in 126±5% of
control current. **p<0.01 and ***p<0.001 compared with DZP
(1 μM); #p<0.05 and ###p<0.01 compared with the respective con-
centration of WYS8. The inset shows examples of current traces of
GABA EC3, WYS8 (100 nM), diazepam (1 μM), and their combina-
tion at α1β3γ2 GABAA receptors
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diazepam was not amenable to amelioration byWYS8. On the
other hand, the influence of the factorWYS8was significant in
the interval 10–15 min (F(3,48)=3.42, p=0.024). Post hoc
comparison among single levels revealed the significant dif-
ference between the 0.2 and 10 mg/kg doses of WYS8 (differ-
ence of means 0.97 m, p=0.015). The significance was based
on the difference within the diazepam (0 mg/kg) but not
diazepam 2 mg/kg dose (respective differences of means
1.18 and 0.76 m), suggesting that in this interval the highest
dose of WYS8 may have exerted a mild sedative-like action.
The interaction between two factors did not reach significance
at either of intervals.
Elevated plus maze
The effect of diazepam as a factor was statistically signifi-
cant for both the activity-related parameters (for total
distance (Fig. 5a): F(2,72)=7.20, p=0.001; for closed arm
entries (Fig. 5b): F(2,72)=7.61, p=0.001) and the anxiety-
related parameters (for percent of open arm time (Fig. 5c)—
F(2,72)=4.60, p=0.013; for percent of open arm entries
(Fig. 5d)—F(2,72)=3.82, p=0.027), as analyzed with a
two-way ANOVA. The respective F values (F(3,72)) for
WYS8 as a factor were, for activity-related parameters,
F=2.53 (p=0.064) and F=3.35 (p=0.024) while, for
anxiety-related parameters, F=0.18 (p=0.91) and
F=0.66 (p=0.577). The interaction between two factors
was not significant in either of the analyses.
For both activity-related parameters, post hoc comparisons
revealed a significant overall difference in the influence of the
2 mg/kg diazepam versus 0 mg/kg as well as 1 mg/kg dose. As
shown in the Fig. 4a, b, this difference existed within the
10 mg/kg dose of WYS8. Within the 1 mg/kg dose of
WYS8, 2 mg/kg diazepam decreased the number of closed
arm entries in comparison to the lower dose. Similarly, the
dose of 10 mg/kg of WYS8 exerted a significant overall
decrease of closed arm entries relative to the 0 and 1 mg/kg
doses ofWYS8.Within the 2 mg/kg diazepam level, the effect
of the 10 mg/kg dose of WYS8 was significant when com-
pared with each of three other levels of WYS8; the latter also
applies to the parameter of the total distance. In regard to the
anxiety-related parameters, 2 mg/kg diazepam significantly
increased both, the percent of open arm time and percent of
open arm entries in comparison with the control group; for the
latter parameter, there was also difference between the 0 and
1 mg/kg dose of diazepam. As shown in Fig. 4d, there was
also a significant increase of percent of open arm entries with
2 mg/kg diazepam when compared with 1 mg/kg but only
within the 0.2 mg/kg dose of WYS8. Within this level of
WYS8, there existed a clear statistical trend toward revealing
the anxiolytic effect of diazepam, implied by an increase in
both the percent of open arm time (p=0.068 for 2 versus
0 mg/kg diazepam and p=0.061 for 2 mg/kg versus 1 mg/kg
diazepam) and the percent of open arm entries (p=0.065 for 2
versus 0 mg/kg diazepam).
Fig. 3 The effects of WYS8 (0, 0.2, 1, and 10 mg/kg) in the absence
(DZP 0) and the presence of 2 mg/kg diazepam (DZP 2), on the total
distance traveled in the activity chamber during 30 min of recording.
Data points represent means±SEM. *p<0.05 compared with DZP
0 within WYS8 0. Number of animals per each treatment was 7
Fig. 4 The effects of WYS8 (0, 0.2, 1, and 10 mg/kg) in the absence
(DZP 0; closed circles) and the presence of 2 mg/kg diazepam (DZP 2;
closed triangles), on the distance traveled in the activity chamber
during six consecutive 5-min intervals. Data points represent means.
*p<0.05 and **p<0.01 compared with DZP 0 within the appropriate
dose of WYS8
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Grip strength
The two-way ANOVA of the results obtained in the grip
strength test (Fig. 6) showed that both, diazepam (F(1,45)=
22.03, p<0.001) and WYS8 (F(3,45)=8.36, p<0.001) exerted
a highly significant influence. Since a significant interaction
between diazepam and WYS8 was also determined (F(3,45=
10.35, p<0.001), we decided to use one-way ANOVAs (for
each of two levels of factor diazepam) and Student’s t tests (for
each of four levels of factorWYS8) to fully examine the simple
main effects of both factors. One-way ANOVAs revealed the
borderline significance of WYS8 effect within the factor diaz-
epam 0 (F(3,24)=2.999, p=0.050) but a highly significant
effect within diazepam 2 (F(3,21)=15.412, p<0.001). Post
hoc analysis further revealed a significant difference between
each level of WYS8, except for 10 versus 0.2 mg/kg WYS8
comparison. Student’s t tests applied on diazepam data within
different levels of WYS8 (0, 0.2, and 10 mg/kg, but not
1 mg/kg) showed a highly significant difference between the
two levels of diazepam, revealing that the incapacitating effect
of diazepam (2 mg/kg) was amenable to antagonism byWYS8
only at 1 mg/kg.
Fig. 5 The effects of diazepam (DZP; 0, 1, and 2 mg/kg) and WYS8
(0, 0.2, 1, and 10 mg/kg) on the a total distance traveled, b number of
closed arm entries, c percentage of time spent on open arms, and d
percentage of entries in open arms of the elevated plus maze. Data
points represent means+SEM. **p<0.01 compared with the DZP
0 group within the appropriate dose of WYS8; +p<0.05 and ++p<
0.01 compared with the DZP 1 group within the appropriate dose of
WYS8. Number of animals per each treatment was 7
Fig. 6 The effects of WYS8 (0, 0.2, 1, and 10 mg/kg) in the absence
(DZP 0) and the presence of diazepam 2 mg/kg (DZP 2), on the muscle
tone measured in the grip strength test. Data points represent means±
SEM. **p<0.01 and ***p<0.001 compared with the DZP 0 group
within the appropriate dose of WYS8; ++p<0.01 and +++p<0.001
compared with the WYS8 0+DZP 2 group; ##p<0.01 compared with
the WYS8 0.2+DZP 2 group; †p<0.05 compared with the WYS8 1+
DZP 2 group. Number of animals per treatment was 6, with the
exception of WYS8 0.2 (n=10) and DZP 2+WYS8 10 group (n=7)
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Rotarod
According to the two-way ANOVA, the effect of diaz-
epam as a factor was highly significant (F(2,80)=49.75,
p<0.001); the influence of WYS8 as well as diazepam×
WYS8 interaction were insignificant (F(3,80)=0.77,
p=0.53 and F(6,91) = 0.38, p=0.89, respectively)
(Fig. 7). Post hoc analysis has shown that 2 mg/kg
diazepam significantly decreased rotarod performance
in comparison to two other levels of diazepam (0 and
0.5 mg/kg) in the presence as well as in the absence of any
dose of WYS8, showing that the incapacitating effect of
diazepam in the rotarod test was not amenable to
amelioration.
Pentylenetetrazole test
Chi-square test has shown that there was an overall
difference in the frequency of incidence of clonic or
tonic convulsions (χ2=15.17; p=0.034) (Fig. 8). Fisher
exact test revealed that diazepam was effective in
protecting the animals against convulsions induced by
pentylenetetrazol (p=0.019). On the other hand, WYS8
on its own did not assure any reliable protection; more-
over, there was a trend of dose-dependent deterioration in
test performance (Fisher’s exact test between 0.2 and
10 mg/kg doses of WYS8 was 0.093). The protective
effect of diazepam disappeared when WYS8 was added,
suggesting that full positive modulation at α1 subunit-
containing GABAA receptors was necessary for exerting
the anticonvulsive effect of diazepam.
Discussion
The α1 GABAA receptor population comprises more than
50 % of all GABAA receptors when receptors containing α1
and another type of α subunit are added (Olsen and Sieghart
2008). Although elegant genetic studies with diazepam as a
pharmacological tool revealed a crucial role of this major
receptor class in the processes controlling sedation, motor
coordination, and, in part, epileptic propensity (Rudolph and
Möhler 2004), the results of these studies on their own are
not sufficient to explain the complexity of findings obtained
with novel ligands reportedly inactive at α1 GABAA re-
ceptors (Skolnick 2012). In order to further elucidate this
issue, it seems necessary to use pharmacologically selective
modulation of effects of standard BZs at these receptors in
wild-type animals. We have recently shown that WYS8, one
of the most selective ligands for α1 GABAA receptors
reported to date (Yin et al. 2010), acts as a weak partial
positive modulator at these receptors, devoid of behavioral
activity in the water maze paradigm (Joksimović et al.
2013). Here, we report on the influence of WYS8 on
diazepam-induced potentiation of recombinant GABAA re-
ceptors, and also on the further behavioral characterization
in rats of WYS8 on its own and in combination with
diazepam.
Twenty minutes after intraperitoneal injection, WYS8 at
the dose of 10 mg/kg gave rise to a brain concentration of
approximately 100 nM (Joksimović et al. 2013); at this
concentration in vitro, WYS8 exerted weak potentiation of
α1 GABAA receptors, a borderline influence at α2-, α3-, and
Fig. 7 The effects of diazepam (DZP; 0, 0.5, and 2 mg/kg) and WYS8
(0, 0.2, 1, and 10 mg/kg) on the time of rotarod performance. Data
points represent means±SEM. ***p<0.001 compared with the DZP
0 group within the appropriate dose of WYS8; +++p<0.001 compared
with the DZP 0.5 group within the appropriate dose of WYS8. Number
of animals per treatment was 6–10, in total 92
Fig. 8 The percent of non-convulsant (protected) animals treated with
solvent (SOL), diazepam (DZP; 2 mg/kg), and WYS8 (0.2, 1, and
10 mg/kg), on their own and in combination, in the pentylenetetrazole
test. Data points represent means. *p<0.05 compared with the SOL
group; ++p<0.01 compared with the DZP 2 group. Number of animals
per treatment was 6–12, in total 61
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α4 GABAA receptors, and a lack of action at α5- and
α6β3γ2 GABAA receptors (present study). Such a pattern
of activity could be related to the high affinity of WYS8 for
α1β3γ2 GABAA receptors and low affinity for other,
non-α1β3γ2 receptors (Yin et al. 2010 and unpublished
results of BL Roth et al.). Moreover, the activity of
WYS8 at rat recombinant α1β3γ2 receptors was not
substantially different from that at β1- or β2-containing
α1 GABAA receptors, reproducing previous findings in-
dicating that the subtype of β subunit does not signifi-
cantly influence the effects of BZs at GABAA receptors
(Hadingham et al. 1993).
Our unpublished data indicate that brain concentration of
diazepam, measured 20 min after intraperitoneal adminis-
tration of the 2 mg/kg dose, was approximately 1 μM, which
is comparable to the concentration range reported in previ-
ous studies (Hironaka et al. 1984; Friedman et al. 1986). The
present two-electrode voltage clamp results revealed that
100 nM WYS8 inhibited the diazepam-induced increase of
the GABA current only at α1β3γ2 GABAA receptors. A
similar attenuating effect of WYS8 at these receptors was
also observed when it was applied at tenfold higher (1 μM)
but not at tenfold lower (10 nM) concentration, which in-
dicates that the antagonizing effect of WYS8 was
concentration-dependent. Taking all these in vitro results
together, it appears that the efficacy profile of WYS8 re-
inforces its affinity data (Yin et al. 2010), indicating that it is
one of the most selective ligands for α1 GABAA receptors.
In addition to these lines of evidence, two caveats should
be also addressed. Firstly, it is postulated that the channel-
forming subunits expressed in cell lines cannot necessarily
reproduce all properties of neuronal receptors (Birnir and
Korpi, 2007), and, hence, native GABAA receptors may
behave differently than recombinant receptors in an expres-
sion system (cf. Helms et al. 2012). This possibility, how-
ever, currently cannot be investigated in the absence of a
clear and highly specific electrophysiological and pharma-
cological signature of the individual receptor subtypes that
would allow their unequivocal identification in single-
channel measurements from brain tissue. Secondly, synaptic
GABAA receptors are expected to experience a brief high,
rather than the low concentration of GABA, used in our
study. As discussed in the methods section, “Experimental
procedures,” however, the effects of benzodiazepine site
ligands at high GABA concentrations cannot be reliably
measured due to the rapid desensitization of receptors that
antagonizes the prolonged decay of GABA-induced currents
elicited by such drugs under these conditions. Moreover,
such a low GABA concentration corresponds well with that
occurring at extrasynaptic receptors, which represent the
majority of GABAA receptors in the brain (Kasugai et al.
2010), including substantial numbers of those containing the
γ2 subunit (Olsen and Sieghart 2008).
In the current behavioral characterization, diazepam, as a
standard non-selective BZ, has expectedly engendered all
the sedative, anxiolytic, muscle relaxant, ataxic, and anti-
convulsant effects. On the other hand, WYS8 on its own
was essentially devoid of BZ-like actions and only exhibited
a hint of sedative-like potential at the highest tested dose of
10 mg/kg. This experimental finding suggests that a mild
grade of sedation may be connected even with relatively
small potentiation of α1 GABAA receptors. Interestingly, a
comparable degree of α1 GABAA receptor activation in-
duced by another partial positive modulator (MRK-409)
has been discussed as possibly contributing to sedation in
humans, an effect previously undetected in animal studies
(Atack et al. 2011).
In regard to the activity-related parameters, it was evident
in the spontaneous locomotor activity test that WYS8 may
attenuate diazepam-induced locomotor depressant (i.e., sed-
ative) effect, at least when overall activity was analyzed.
Namely, there existed an interval (between 5 and 10 min
after starting the test) when sedation was observable, despite
the presence of WYS8. In the plus-maze, the activity-related
parameters were changed in a different manner. In accor-
dance with the enhanced aversiveness of the test conditions
and the supposed higher baseline performance than in spon-
taneous locomotor test (Hogg 1996), diazepam on its own
did not induce overt sedation, while addition of WYS8,
especially at the highest dose, resulted in a significant de-
pression of locomotion. Even though in vitro data showed
that WYS8 significantly reduced diazepam’s potentiation of
α1 GABAA receptors, it seems that administration of
WYS8, depending on the behavioral task as well as time
interval, could contribute to, deduct from, or leave
unchanged the sedative action of diazepam in rats.
We have previously shown that selective antagonism at
α1 GABAA receptors by β-CCt may potentiate the anxio-
lytic effect of midazolam in the plus-maze (Savić et al.
2004). However, there were also opposite results showing
that β-CCt was effective in antagonizing the anxiolytic-like
influences of BZs (Belzung et al. 2000; Griebel et al. 1999).
The present results revealed that a small dose (0.2 mg/kg) of
the α1-selective moderate positive modulator may unmask
the anxiolytic action of the higher of the two tested doses of
diazepam, possibly by reducing the overall activity at α1
GABAA receptors through competition for the same binding
sites and relative decrease of receptors occupied by the full
positive modulator such as diazepam. This finding implies
that the effects (most probably sedation) mediated by α1
GABAA receptors may have hampered the anxiolytic ac-
tions of diazepam effected by other receptor subtypes. As a
corollary, it cannot be excluded that a distinct level of
activation of α1 GABAA receptors may directly contribute
to the anxiolytic-like action of BZs (cf. Lippa et al. 2005;
Smith et al. 2012).
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The study with β-CCt in monkeys (Licata et al. 2009) has
indirectly supported the conclusion from knock-in mice that
α2 GABAA, and, to a lesser degree, α3 GABAA receptors
are mainly involved in the muscle relaxation produced by
BZs (Crestani et al. 2001). In the current grip strength test,
WYS8, while having no effect per se, attenuated the
myorelaxant effect of diazepam (2 mg/kg), especially at
the 1 mg/kg dose; this finding was similar to the effect of
β-CCt in the same test in rats (Milić et al. 2012). The results
from the loaded grid test in mice have shown that β-CCt
may significantly diminish the myorelaxant effect of diaze-
pam administered at an intermediate dose of 3 mg/kg but not
at doses of 1 or 10 mg/kg (Griebel et al. 1999). With these
findings in mind, the present results suggest that muscle
relaxation mediated by α2 and α3 GABAA receptors is
somehow regulated by α1 GABAA receptors, the particular
manifestation of which depends on the relative level of
activity at all three involved receptors.
The studies in monkeys (Licata et al. 2009; Platt et al.
2002) and knock-in mice (McKernan et al. 2000) have
suggested that diazepam-induced loss of motor coordination
is predominantly mediated by activation of α1 GABAA re-
ceptors. Our recent results showed that the application of β-
CCt fully antagonized the impairment of motor coordination
induced by diazepam as well as zolpidem (Milić et al.
2012). The level of selective positive modulation at α1
GABAA receptors obtained by WYS8 on its own was not
sufficient to engender ataxia. However, the observed reduc-
tion of diazepam-induced activation at this receptor popula-
tion, effected by WYS8 in vitro, was not sufficient even for
attenuation of the diazepam’s ataxic effect. These pieces of
evidence suggest that some other, non-α1 GABAA receptors
may contribute to the ataxia, in settings when a moderate
level of activation of α1 GABAA receptors does exist.
The results from the pentylenetetrazole test revealed that
the anticonvulsant effect of diazepam diminishes greatly
when its activity at α1 GABAA receptors is reduced by
WYS8. Moreover, even a hint of proconvulsant action of
10 mg/kg WYS8 was noticed. In mice, it was shown that β-
CCt did not affect the protective action of diazepam on
pentylenetetrazole-induced convulsions (Griebel et al.
1999). Having in mind reports on the anticonvulsant activity
of some ligands mainly inactive at α1 GABAA receptors
(Atack et al. 2006; Rivas et al. 2009), it appears that α1
GABAA receptors may exert a kind of permissive action on
the anti-convulsant activity of BZs mediated through
non-α1 GABAA receptors: The effect may be present when
these receptors are potentiated fully or not at all, rather than
in the case of a partial effect.
In conclusion, the partial activation at α1 GABAA re-
ceptors effected by WYS8 may induce only negligible be-
havioral consequences. Its combination with diazepam was
connected with a reduced sedation, muscle relaxation, and
anticonvulsant activity, as compared with diazepam alone,
whereas ataxia was preserved, while the anxiolytic effect of
2 mg/kg diazepam became unmasked. The anxiolytic and
myorelaxant activity, although probably not attainable with-
out positive modulation at the α2/α3-containing receptors,
are prone to changes in both directions in dependence on the
level of modulation at α1 GABAA receptors. On the con-
trary, although it seems clear that anticonvulsant and even
ataxic actions are attainable without substantial positive
modulation at α1 GABAA receptors, a strong activation of
these receptors may be needed for the full-blown manifes-
tation of these effects. Concerning efforts to develop novel
BZ-like drugs, it appears that the relation between the ac-
tivity at α1 GABAA receptors and overall behavioral output
is not simply “the less, the better”, underlying the impor-
tance of a correct balance rather than individual actions at
different GABAA receptor subtypes.
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